Business Description
X4 Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US98420X2027
Total Employee Number:
45Description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | -0.86 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1 | |||||
Beneish M-Score | -1.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 66.2 | |||||
3-Year EPS without NRI Growth Rate | 64.3 | |||||
3-Year FCF Growth Rate | 61.4 | |||||
3-Year Book Growth Rate | -51.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.75 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.13 | |||||
9-Day RSI | 50.57 | |||||
14-Day RSI | 51.01 | |||||
3-1 Month Momentum % | -4.72 | |||||
6-1 Month Momentum % | 3.86 | |||||
12-1 Month Momentum % | 104.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.18 | |||||
Quick Ratio | 9.98 | |||||
Cash Ratio | 9.83 | |||||
Days Inventory | 866.51 | |||||
Days Sales Outstanding | 34.26 | |||||
Days Payable | 1543.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -181.9 | |||||
Shareholder Yield % | 0.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.82 | |||||
Operating Margin % | -1084.38 | |||||
Net Margin % | -1106.3 | |||||
EBITDA Margin % | -997.14 | |||||
FCF Margin % | -1030.05 | |||||
OCF Margin % | -1030.05 | |||||
ROE % | -112.48 | |||||
ROA % | -51.97 | |||||
ROIC % | -256.57 | |||||
3-Year ROIIC % | -87.29 | |||||
ROC (Joel Greenblatt) % | -3850.64 | |||||
ROCE % | -54.26 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.57 | |||||
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.73 | |||||
EV-to-EBIT | -2.55 | |||||
EV-to-EBITDA | -2.58 | |||||
EV-to-Revenue | 25.75 | |||||
EV-to-Forward-Revenue | 22.98 | |||||
EV-to-FCF | -2.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.77 | |||||
| Price-to-Net-Cash | 2.94 | |||||
Earnings Yield (Greenblatt) % | -39.22 | |||||
FCF Yield % | -23.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XFOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
X4 Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.014 | ||
| EPS (TTM) ($) | -4.583 | ||
| Beta | 0.0918 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.5 | ||
| Volatility % | 127.87 | ||
| 14-Day RSI | 51.01 | ||
| 14-Day ATR ($) | 0.274008 | ||
| 20-Day SMA ($) | 4.03675 | ||
| 12-1 Month Momentum % | 104.04 | ||
| 52-Week Range ($) | 1.35 - 4.83 | ||
| Shares Outstanding (Mil) | 94.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
X4 Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
X4 Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 33 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 3.97 (-1.73%) | ||
| General meeting for 2026 | 2026-05-11 12:00 | 4.43 (+1.84%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 4.20 (-0.71%) | ||
| Annual report for 2025 | 2026-03-17 | 3.56 (-2.20%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 3.56 (-2.20%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 10:00 | 4.66 (+10.69%) | ||
| Guggenheim Second Annual Healthcare Innovation Conference | 2025-11-10 08:30 | 3.71 (+6.61%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 3.97 (-0.75%) |
Show
Entries
X4 Pharmaceuticals Inc Frequently Asked Questions
What is X4 Pharmaceuticals Inc(XFOR)'s stock price today?
The current price of XFOR is $4.12. The 52 week high of XFOR is $4.83 and 52 week low is $1.35.
When is next earnings date of X4 Pharmaceuticals Inc(XFOR)?
The next earnings date of X4 Pharmaceuticals Inc(XFOR) is 2026-08-07 Est..
Does X4 Pharmaceuticals Inc(XFOR) pay dividends? If so, how much?
X4 Pharmaceuticals Inc(XFOR) does not pay dividend.
Guru Commentaries on NAS:XFOR
No articles.
Press Release
Articles on X4 Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers